34results about How to "Less reversible" patented technology

The present invention relates to pyrazinoylguanidine compounds represented by formula (I): where at least one of R3 and R4 is a group represented by formula (A): where the other structural groups are defined herein. The present invention also includes a variety of methods of treatment using these sodium channel blockers.

The present invention relates to compounds represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.

The present invention relates to a compound represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are as defined herein. The compounds are useful for blocking sodium channels.

The present invention relates to compounds represented by formula (I):in which at least one of R3 and R4 is a group represented by formula (A):where the structural variables are defined herein. The compounds are useful for blocking sodium channels.

The present invention provides sodium channel blockers represented by formula (I):where the structural variables are defined herein. The compounds of the present invention may be used for treating a variety of conditions as described herein.

The present invention provides a pyrazinoylguanidine compound represented by formula (I):where the structural variables are as defined herein. The compounds are useful for promoting hydration of mucosal surfaces.

The present invention provides compound represented by formula (I):where the structural variables are defined herein. The compounds function as sodium channel blockers and may be used to treat a variety of respiratory conditions.

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

The present invention relates to pyrazinoylguanidine compounds represented by formula (I):where the structural variables are defined herein. The compounds are useful as, for example, sodium channel blockers.

Polyaromatic sodium channel blockers represented by the formula:are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.

The present invention provides compounds represented by formula (I):where the structural variables are defined herein. The compound of the present invention are useful as sodium channel blockers.

The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.

Provided is class of sodium channel blockers. One example of such a compound is shown by the following formula:The compounds are useful for promoting hydration of mucosal surfaces and treating a variety of disease conditions.

The present invention relates to methods and compositions for treating diseases ameliorated by increased mucociliary clearance and mucosal hydration by administering an effective amount of a sodium channel blocker as defined herein and an osmolyte to a subject to a subject in need of increased mucociliary clearance and mucosal hydration.

The present application provides sodium channel blockers exemplified by the following structure:The compounds of the invention useful for treating chronic bronchitis, cystic fibrosis, sinusitis, vaginal dryness, dry eye, Sjogren's disease, distal intestinal obstruction syndrome, dry skin, esophagitis, dry mouth (xerostomia), nasal dehydration, ventilator-induced pneumonia, asthma, primary ciliary dyskinesia, otitis media, chronic obstructive pulmonary disease, emphysema, pneumonia, constipation, and chronic diverticulitis, for example.

The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.

A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.

Sodium channel blockers represented by the formula:are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.